Shorted
Arovella Therapeutics logo
ALA
Pharmaceuticals, Biotechnology & Life Sciences

Arovella Therapeutics

Short interest
0.00%
0.00 pp 30d
as of 16 June 2026
Reported shorts
1.8K
Shares on issue
1.209B

Arovella Therapeutics (ALA) company profile

Profile, insiders and operations

Company

AI-generated research profile of Arovella Therapeutics

biotechnology
cancer treatment
cell therapy
pharmaceuticals
innovative medicine

Arovella Therapeutics Limited is a biotechnology company developing a platform of invariant Natural Killer T (iNKT) cells for treating cancer. The company aims to harness this platform to create innovative and targeted cancer therapies, positioning itself at the forefront of biotechnology advances. Arovella's unique approach targets unmet medical needs, offering potential breakthroughs in cancer treatment.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-06-10Unknown Director
buy
---
2026-06-09David John Williams
buy
200,000$0.067$13,400
2025-11-25Unknown Director
buy
---
2025-11-24Elizabeth Stoner
exercise options
1,157,647$0.047$54,663.53
2025-11-13Unknown Director
buy
---
2025-11-12Debora Barton
exercise options
1,013,333--
2025-11-11Unknown Director
buy
---
2025-11-10Michael Baker
exercise options
2,991,266--
2025-10-15Unknown Director
buy
---
2025-10-13Michael Baker
exercise options
1,617,021--
2024-11-29Unknown Director
buy
---
2024-11-26Debora Barton
exercise options
974,000--
2024-04-03Unknown Director
buy
---
2024-04-02Unknown Director
buy
---
2024-03-28Dr Thomas Duthy
buy
103,000$14935.000$1,538,305,000
2024-03-28Gary Phillips
buy
66,666$10000.000$666,660,000
2024-03-28Unknown Director
buy
---
2024-03-27Michael Baker
buy
220,000$0.142$31,289.96
2024-01-02Unknown Director
buy
---
2023-12-29Michael Baker
exercise options
587,824--

ALA intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required